Education
About Us
Working with TipRanks
Follow Us
Rocket Pharma (DE:9IP1)
:9IP1
9IP1 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€8.54 - €25.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€870.09M
Enterprise Value€1.53B
Total Cash (Recent Filing)$111.36M
Total Debt (Recent Filing)$41.45M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
May 07, 2025EPS Estimate
-0.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.53
Shares Outstanding106,629,700
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-215.43
Enterprise Value/Ebitda-6.19
Forecast
1Y Price Target
€36.61Price Target Upside320.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
---
Rocket Pharmaceuticals News
PremiumCompany Announcements
Rocket Pharmaceuticals Advances Gene Therapy Pipeline
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe company recently reported impressive Phase 1 durability data for its gene therapy, RP-A501, in Danon disease.
Financial StabilityManagement expects the total cash to support a runway into the third quarter of 2026, indicating financial stability.
Bears Say
Financial ConcernsThe price target is lowered to $42, accounting for increased dilution and pushing back launch timing estimates in LAD-I, FA and DD.
---
Options Prices
Currently, No data available
---
Ownership Overview
35.23% Insiders
22.38% Mutual Funds
8.05% Other Institutional Investors
22.09% Public Companies and Individual Investors
9IP1 FAQ
What was Rocket Pharma’s price range in the past 12 months?
Rocket Pharma lowest stock price was €8.54 and its highest was €25.40 in the past 12 months.
What is Rocket Pharma’s market cap?
Rocket Pharma’s market cap is €870.09M.
When is Rocket Pharma’s upcoming earnings report date?
Rocket Pharma’s upcoming earnings report date is May 07, 2025 which is in 58 days.
How were Rocket Pharma’s earnings last quarter?
Rocket Pharma released its earnings results on Feb 27, 2025. The company reported -€0.597 earnings per share for the quarter, beating the consensus estimate of -€0.691 by €0.094.
Is Rocket Pharma overvalued?
According to Wall Street analysts Rocket Pharma’s price is currently Undervalued.
Does Rocket Pharma pay dividends?
Rocket Pharma does not currently pay dividends.
What is Rocket Pharma’s EPS estimate?
Rocket Pharma’s EPS estimate is -0.58.
How many shares outstanding does Rocket Pharma have?
Rocket Pharma has 106,629,700 shares outstanding.
What happened to Rocket Pharma’s price movement after its last earnings report?
Rocket Pharma reported an EPS of -€0.597 in its last earnings report, beating expectations of -€0.691. Following the earnings report the stock price went down -0.299%.
Which hedge fund is a major shareholder of Rocket Pharma?
Currently, no hedge funds are holding shares in DE:9IP1
---
Rocket Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€36.61 (320.28% Upside)
€36.61 (320.28% Upside)
Blogger Sentiment
Bullish
DE:9IP1 Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $533.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.83%
12-Months-Change
Fundamentals
Return on Equity
-54.14%
Trailing 12-Months
Asset Growth
-6.82%
Trailing 12-Months
Company Description
Rocket Pharma
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
---
9IP1 Stock 12 Month Forecast
Average Price Target
€36.61
▲(320.28% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering 9IP1
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+9.98%
reiterated a buy rating 4 months ago
Copying Greg Harrison's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +9.98% per trade.
---